|
|
Upfront Briefing
WCLC in Seoul handed out the weekend's real news, and it arrived with a coincidence. Two China-run B7-H3 ADCs — GSK and Hansoh's risvutatug rezetecan, Roche and MediLink's tambotatug pelitecan — each cut the risk of death by exactly 54% versus topotecan in relapsed small-cell, presented back to back at the Presidential Symposium. Same hazard ratio, different drugs, different control arms. Daiichi Sankyo and Merck's ifinatamab, sitting on a priority-review BLA built on single-arm data, suddenly has two randomised benchmarks to be measured against. Elsewhere the lung firehose ran both ways: Akeso and Summit's ivonescimab finally produced survival over Keytruda, J&J's Rybrevant posted the longest OS ever reported in EGFR exon 20, Enhertu's first-line data carried more deaths than control, Trodelvy missed outright, and AstraZeneca's Etcamah flunked first-line breast — another name on the oral SERD casualty list.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,657.0 |
+0.9% |
11.6% |
| Nasdaq 100 |
29,368.4 |
+0.9% |
16.5% |
| Russell 2000 |
2,903.9 |
+0.5% |
15.8% |
| Healthcare (XLV) |
165.4 |
(0.2%) |
6.8% |
| Biotech (XBI) |
156.2 |
(0.4%) |
28.5% |
| Nasdaq Biotech (NBI) |
6,924.7 |
0.7% |
21.3% |
| Clinical Trials (BBC) |
49.4 |
(1.1%) |
31.2% |
|
- Biotech lagged a broadly green Friday tape: XBI (0.4%) and BBC (1.1%) against XLV (0.2%), with NBI flat — clinical-stage and small-cap names giving back ground while large-cap healthcare held.
- The broad tape rebounded, with the S&P 500 and Nasdaq 100 each up 0.9%, as crude gave back 2.4% to $100.05 and the VIX fell 11.2% to 15.84 — unwinding the oil-and-PPI inflation scare that drove Thursday's selloff.
- Market data: U.S. cash close Friday, 11 September 2026.
The Big 3
|
1
|
B7-H3 ADCs deliver matching 54% survival wins for GSK and Roche
|
- GSK and Hansoh's risvutatug rezetecan (ARTEMIS-008) and Roche and MediLink's tambotatug pelitecan (TAISHAN-302) each reduced the risk of death by 54% versus topotecan in relapsed small-cell lung cancer, presented back to back at the WCLC Presidential Symposium in Seoul on 13 September.
- Why it matters: First Phase 3 overall-survival wins for the B7-H3 class in any tumour type, and they landed an hour apart. Ris-Rez posted 18.5 months median OS against 10.3 on topotecan, with ORR 58.3% versus 12.6%; Tam-Peli posted 13.3 versus 9.4 across 451 patients at 85 sites. The matching HR of 0.46 is coincidence, not comparability — the control arms survived four months apart. The read-through runs to Daiichi Sankyo and Merck, whose ifinatamab deruxtecan holds a priority-review BLA in this setting on single-arm Phase 2 data and now has two randomised benchmarks sitting beside it. Both trials ran entirely in China, which puts COINS Act overhang and FDA single-region-data scepticism on the registration path.
- Source: Fierce Biotech
- More: ILCN; PR Newswire
|
|
2
|
Ivonescimab finally beats Keytruda on survival
|
- Akeso and Summit's PD-1xVEGF bispecific ivonescimab showed a statistically significant overall-survival benefit over pembrolizumab monotherapy in first-line PD-L1-positive NSCLC, with interim HARMONi-2 data presented at WCLC as a late-breaking abstract.
- Why it matters: Fourth Phase 3 OS hit for ivonescimab, and the first head-to-head survival win over Keytruda monotherapy anywhere. The trial that created the PD-1xVEGF class on PFS in May 2024 has now closed the loop. Akeso rose 3.4% in Hong Kong, which tells you the bar had already moved: an unplanned Chinese-regulator interim in April 2025 leaked a 22.3% death-risk reduction and took Summit's stock apart on the size of the early benefit. HARMONi-2 is China-only and ivonescimab remains investigational in the US, so what prices Summit is still the global HARMONi programme, not this readout. For Merck, it is the first randomised survival loss for Keytruda in this setting.
- Source: Fierce Pharma
- More: BioSpace
|
| 3 | Etcamah flunks first line four days after its approval |
- AstraZeneca's oral SERD Etcamah (camizestrant) missed in a first-line HR+/HER2-negative advanced breast cancer trial, adding to the oral SERD class's record of front-line failures.
- Why it matters: The same molecule cleared FDA approval on 8 September for ctDNA-triggered switching and flunked first line four days later. That approval rests on catching emergent ESR1 mutations in an already-treated population — a selected, sequential market. The failed trial asked the oral SERD to win front line, where every entrant in the class has now come up short. It narrows Etcamah to a mutation-selected opportunity rather than the broad franchise the bulls underwrote, and it does the same to the read-across names: Lilly's imlunestrant, Roche's giredestrant and the Arvinas and Pfizer degrader all carry front-line ambitions on the same biology and the same comparator problem.
- Source: Fierce Pharma
|
Everything Else that broke
- J&J's Rybrevant plus carboplatin-pemetrexed delivered 34.3 months median OS versus 27.9 on chemotherapy alone in first-line EGFR exon 20 insertion NSCLC (n=308) in the final PAPILLON analysis, the longest reported in the setting despite 76% crossover. — PR Newswire
- Cullinan and Taiho's zipalertinib plus chemotherapy improved median progression-free survival by 6.0 months (14.5 vs 8.5, HR 0.50, p=0.00015) in first-line EGFR exon 20 NSCLC in REZILIENT3 (n=279), with ORR 65% vs 40.3%; overall survival is immature at 30% events, HR 0.72. — Fierce Biotech
- Scholar Rock's Isembyld won FDA approval as the first SMA drug targeting muscle loss. — STAT
- Enhertu's first-line HER2-mutant NSCLC readout carried a preliminary 15% higher death risk. — Fierce Pharma
- Trodelvy plus pembrolizumab missed primary endpoints in first-line PD-L1-high metastatic NSCLC. — PR Newswire
- The same failed Trodelvy trial read better in its China subset than in the overall population. — Fierce Pharma
- Kelun-Biotech published phase 3 trastuzumab botidotin data versus T-DM1 in HER2-positive breast cancer in JCO. — PR Newswire
- GSK is preparing a frontline FDA submission for Jideytro, its first lung cancer drug. — Fierce Pharma
- The FDA pushed its decision on Exelixis' zanzalintinib plus Roche's Tecentriq in previously treated metastatic colorectal cancer out three months from the 3 December PDUFA date; STELLAR-303 hit its ITT overall-survival co-primary (HR 0.80, 10.9 vs 9.4 months against regorafenib) but missed the non-liver-metastases co-primary at final analysis in June. — Fierce Biotech
- Separately, the FDA cleared a novel Cabometyx formulation, which analysts expect to pose limited competitive threat to Exelixis. — Fierce Pharma
- Daiichi Sankyo won $1.3B in a US patent judgment. — Fierce Pharma
- Intuitive won an expanded European indication for da Vinci SP in gynecologic procedures. — PR Newswire
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- GE HealthCare is reportedly weighing a roughly $1B acquisition of Sofie Biosciences in imaging chemicals, per the Financial Times. — Fierce Biotech
- Samsung Biologics signed a $262M manufacturing contract through 2033 with an unnamed European pharma company. — BioSpace
- CDMO Argonaut divested its life sciences and diagnostics division for an undisclosed sum. — Fierce Pharma
VC / Private Financings
- No notable VC or private financings since the last edition.
IPOs / Follow-Ons
- Yarrow Bioscience (YARW) priced 5,769,231 shares at $26.00 for roughly $150M gross, an 8.6% discount to Thursday's $28.44 close, with Jefferies, TD Cowen and Guggenheim book-running and LifeSci Capital as lead manager; proceeds fund YB-101 in Graves' disease and thyroid eye disease. Shares fell about 7%. — BioSpace
Academic Corner
- An explainable multimodal AI tool outperformed established biomarkers for immunotherapy outcome prediction in NSCLC, though generalisability is still a constraint. — Nature Medicine
|
Two identical hazard ratios, three days of lung data, and one very long flight home from Seoul.
— BioBucks Team
|
|
|
